Eli Lilly Reaches Deal in Testosterone Replacement Therapy Multi-district Litigation

Chicago, IL: A global settlement deal has been reached by Eli Lilly and plaintiffs in multidistrict litigation alleging the company’s testosterone replacement therapy is associated with cardiovascular adverse health events.

The deal comes about one month before the first bellwether trial was set to go to court. The judge cancelled two upcoming trial dates in January and March over Tracy Garner and John DeBroka Jr.’s cases alleging that Eli Lilly’s Axiron caused them to suffer from a heart attack and deep vein thrombosis, respectively.

More than 6,000 cases are pending against Eli Lilly, Auxilium and several other pharmaceutical companies in the MDL, all alleging the testosterone replacement therapies caused serious if not irreversible adverse health effects.

The MDL is In Re: Testosterone Replacement Therapy Products Liability Litigation, case number 1:14-cv-01748, in the U.S. District Court for the Northern District of Illinois.

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please fill in our form.
Published on Dec-27-17